LVCG Chairman David Ciclitira is (briefly) back in Europe

I’ve now returned from Asia and wanted to update you on very successful and interesting trip last week, particularly in ASEAN and Japan. BRICKLIVE is gaining traction as a brand and we have new opportunities to close this quarter. Although the entire company is focussed on hitting EBITDA targets for 2019 there are still opportunities to grasp and so now I’m repacking for a trip to the Middle East. My journey to the Gulf has come about after extensive enquiries to partner with the BRICKLIVE brand in the region.

There does not appear to be a profile here yet (if this your your plc please get in touch)
Facebook
Twitter
LinkedIn
Live Company Group PLC

More articles like this

Fidelity Japan Trust

Japanese stocks set to rise after reaching record highs

After topping bubble-era highs, Goldman Sachs Research says Japanese stocks are poised to rise even higher. Japan’s Nikkei 225 stock index closed above 40,000 on March 4, setting another record high after climbing last month above

Norcros Plc

Norcros plc enhances Market Presence with Strategic Moves

Norcros plc (LON:NXR), a prominent supplier of innovative bathroom and kitchen products, continues to make strategic moves to enhance its market presence and financial performance. The recent disposal of Johnson Tiles UK to its management team marks

Accrol Group

What are the latest technology trends in manufacturing?

We asked the FactoryTech 50 and judging panel to describe a particular trend they have noticed in manufacturing technology in the last year. Judge Kevin Smith (below) is lead technology advisor at Made Smarter UK, which has engaged

Team plc

Key Insurance Types in Financial Planning

When it comes to financial planning, different types of insurance serve different purposes. While critical illness insurance can be valuable, the importance of each insurance type may vary depending on a clients individual circumstances and priorities.

Poolbeg Pharma granted significant POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted